Cargando…
Advances in Combination Therapy for Asthma and COPD.
Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hoboken :
John Wiley & Sons,
2011.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn768732463 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 111219s2011 xx o 000 0 eng d | ||
| 010 | |a 2011023057 | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d IDEBK |d OCLCQ |d UKDOC |d OCLCQ |d RECBK |d Z5A |d OCLCQ |d OCLCO |d OCLCF |d ZCU |d OCLCO |d OCLCQ |d MERUC |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d ICG |d VT2 |d OCLCO |d AU@ |d OCLCO |d OCLCQ |d WYU |d OCLCO |d OCLCA |d DKC |d OCLCO |d OCLCQ |d OCLCA |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 927508997 |a 1228579592 | ||
| 020 | |a 9781119998631 | ||
| 020 | |a 1119998638 | ||
| 020 | |a 9780470727027 |q (cloth) | ||
| 020 | |a 0470727020 | ||
| 029 | 1 | |a AU@ |b 000055782732 | |
| 029 | 1 | |a DEBBG |b BV044160286 | |
| 029 | 1 | |a NZ1 |b 16241297 | |
| 035 | |a (OCoLC)768732463 |z (OCoLC)927508997 |z (OCoLC)1228579592 | ||
| 050 | 4 | |a RC776.O3 A33 2011 | |
| 060 | 4 | |a WF 553 | |
| 082 | 0 | 4 | |a 616.2306 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Lotvall, Jan. | |
| 245 | 1 | 0 | |a Advances in Combination Therapy for Asthma and COPD. |
| 260 | |a Hoboken : |b John Wiley & Sons, |c 2011. | ||
| 300 | |a 1 online resource (366 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 505 | 0 | |a ADVANCES IN COMBINATIONTHERAPY FOR ASTHMAAND COPD; Contents; Contributors; Preface; 1 Similarities and differences in the pathophysiology of asthma and COPD; 1.1 Introduction; 1.2 Pulmonary function abnormalities in asthma and COPD; 1.3 Risk factors for asthma and COPD; 1.4 Cellular inflammation in asthma and COPD; 1.5 Distribution and consequences of inflammation in asthma and COPD; 1.6 Patterns of epithelial injury in asthma and COPD; 1.7 Airway hyperresponsiveness; 1.8 Beta-receptor blockers; 1.9 Differential diagnosis of asthma and COPD; 1.10 Overlap syndrome; 1.11 Conclusion; References. | |
| 505 | 8 | |a 2 Glucocorticoids: pharmacology and mechanisms2.1 Introduction; 2.2 Chemical structures; 2.3 The molecular basis of inflammation; 2.4 Cellular effects of glucocorticoids; 2.5 Glucocorticoid receptors; 2.6 Glucocorticoid activation of gene transcription; 2.7 Suppression of inflammatory genes; 2.8 Steroid resistance; 2.9 Interaction with ß2-adrenergic receptors; 2.10 Conclusions; References; 3 Inhaled corticosteroids: clinical effects in asthma and COPD; 3.1 Introduction; 3.2 Anti-inflammatory activity of corticosteroids; 3.3 Routes of administration; 3.4 Absorption and fate of corticosteroids. | |
| 505 | 8 | |a 3.5 Currently available inhaled corticosteroids3.6 Efficacy in asthma; 3.7 Efficacy in COPD; 3.8 Side effects of ICS; 3.9 Conclusions; References; 4 LABAs: pharmacology, mechanisms and interaction with anti-inflammatory treatments; 4.1 Galenical forms of LABAs: formulations, isomers, enantiomers, diasteriomers and salts; 4.2 Absolute and functional ß2-adrenoceptor selectivity; 4.3 Cellular organization of receptor clusters: functional structure of the ß2-adrenoceptor and mode of signalling; 4.4 Dimers and oligomers: homo- and heterodimerism/oligoism. | |
| 505 | 8 | |a 4.5 Pharmacogenomics of the ß2-adrenoceptor and adenylate cyclase polymorphism in relation to LABAs4.6 Understanding the 'reassertion' paradox, 'exosites' and relative speed of onset: the membrane diffusion microkinetic model of LABA action; 4.7 Regulation and desensitization; 4.8 Full versus partial agonism (pharmacological efficacy); 4.9 Beta-blockers not LABAs?; 4.10 Non-receptor-mediated effects?; 4.11 Biochemical basis of functional antagonism and its critical role in LABA action in disease and exacerbations; 4.12 Molecular cooperativity between LABAs and steroids; 4.13 Perspective. | |
| 504 | |a References5 Long-and ultra-long-acting ß2-agonists; 5.1 Introduction; 5.2 Long-acting ß2-agonists; 5.3 Novel ultra-long-acting ß2-agonists; 5.4 Conclusion; References; 6 The safety of long-acting beta-agonists and the development of combination therapies for asthma and COPD; 6.1 Introduction; 6.2 Asthma-related mortality and beta-agonist exposure; 6.3 Long-acting beta-agonists and increased asthma-related mortality; 6.4 Safety and efficacy of LABA therapy in asthma: retrospective analyses. | ||
| 500 | |a 6.5 Efficacy of LABA therapy as a component of combination therapy with ICS for the management of asthma. | ||
| 520 | |a Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy for Asthma and COPD is the first book to address the complexity of multi-agent therapy and deal with management issues in an integrated fashion.€ A review of currently available agents and their applications, as well as new therapies soon to become available are outlined. Advantages of combine. | ||
| 588 | 0 | |a Print version record. | |
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Lungs |x Diseases, Obstructive |x Chemotherapy. | |
| 650 | 0 | |a Asthma |x Chemotherapy. | |
| 650 | 0 | |a Polypharmacy. | |
| 650 | 0 | |a Chemotherapy, Combination. | |
| 650 | 1 | 2 | |a Asthma |x drug therapy |
| 650 | 2 | 2 | |a Drug Therapy, Combination |
| 650 | 2 | 2 | |a Pulmonary Disease, Chronic Obstructive |x drug therapy |
| 650 | 2 | |a Polypharmacy | |
| 650 | 6 | |a Poumons |x Maladies obstructives |x Chimiothérapie. | |
| 650 | 6 | |a Asthme |x Chimiothérapie. | |
| 650 | 6 | |a Polypharmacie. | |
| 650 | 6 | |a Chimiothérapie d'association. | |
| 650 | 7 | |a Asthma |x Chemotherapy |2 fast | |
| 650 | 7 | |a Chemotherapy, Combination |2 fast | |
| 650 | 7 | |a Lungs |x Diseases, Obstructive |x Chemotherapy |2 fast | |
| 650 | 7 | |a Polypharmacy |2 fast | |
| 758 | |i has work: |a Advances in combination therapy for asthma and COPD (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFwXqJrPrKWqYtwp3qcvDy |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Lotvall, Jan. |t Advances in Combination Therapy for Asthma and COPD. |d Hoboken : John Wiley & Sons, ©2011 |z 9780470727027 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=822610 |z Texto completo |
| 938 | |a 123Library |b 123L |n 31814 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL822610 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 340690 | ||
| 938 | |a Recorded Books, LLC |b RECE |n rbeEB00064599 | ||
| 994 | |a 92 |b IZTAP | ||